Exelixis Inc (EXEL)
22.65
-0.11 -0.48%
NASDAQ
Jun 15, 12:40
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 1.031B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 0.205 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 64.77M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | 0.59% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 7.098B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 6.965 |
| PE Ratio | 110.50 |
| Price to Book Value | 3.714 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | 25.99M |
| Return on Equity | Upgrade |
View All EXEL News
News
-
WireHeadlineTime (ET)
-
SA Breaking News06/15 10:56
-
MT Newswires06/15 07:15
-
MT Newswires06/14 08:28
-
Yahoo06/14 08:00
-
Yahoo06/07 08:00
-
Yahoo06/06 10:06
-
MT Newswires06/04 10:26
-
Yahoo06/04 09:00
-
Yahoo06/04 09:00
-
Yahoo06/04 09:00
-
Yahoo05/30 06:00
-
Yahoo05/26 16:15
-
Yahoo05/26 06:06
-
Yahoo05/25 10:51
-
Yahoo05/25 07:48
-
SA Breaking News05/24 16:36
-
Yahoo05/24 16:05
-
Yahoo05/22 06:30
-
Yahoo05/21 06:31
-
Yahoo05/20 01:35
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 08/06/2021 | Earnings Results | Q2 2021 Earnings Results |
| 08/06/2021 17:30 EST | Earnings Calls | Q2 2021 Earnings Call |
| 05/06/2021 | Earnings Results | Q1 2021 Earnings Results |
| 05/06/2021 17:00 EST | Earnings Calls | Q1 2021 Earnings Call |
| 02/10/2021 | Earnings Results | Q4 2020 Earnings Results |
| 02/10/2021 17:00 EST | Earnings Calls | Q4 2020 Earnings Call |
| 11/05/2020 | Earnings Results | Q3 2020 Earnings Results |
| 11/05/2020 17:00 EST | Earnings Calls | Q3 2020 Earnings Call |
| 08/06/2020 17:30 EST | Earnings Calls | Q2 2020 Earnings Call |
| 08/06/2020 | Earnings Results | Q2 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
- URL: https://www.exelixis.com
- Investor Relations URL: https://ir.exelixis.com
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Aug. 06, 2021
- Last Earnings Release: May. 06, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 22.65 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| VLLIX | Value Line Larger Companies Focus Instl | 5.54% |
| VLIIX | Value Line Capital Appreciation Instl | 4.54% |
| IDNA | iShares Genomics Immnlgy & Hlthcr ETF | 4.42% |
| FBT | First Trust NYSE Arca Biotech ETF | 2.98% |
| FIJYX | Fidelity Advisor® Biotechnology Z | 2.96% |
| CAMUX | Cambiar SMID Institutional | 2.65% |
| PBE | Invesco Dynamic Biotech & Genome ETF | 2.59% |
| BBP | Virtus LifeSci Biotech Products ETF | 2.29% |
| PXSAX | Pax Small Cap A | 1.58% |
| HQL | Tekla Life Sciences Investors | 1.36% |
| FBIOX | Fidelity® Select Biotechnology | 1.24% |
| HQH | Tekla Healthcare Investors | 0.99% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- EXEL Tweets Stocktwits
Advertisement
